Efficacy of once-weekly dulaglutide on HbA1c reduction in East Asian patients with T2DM: subgroup analysis according to potential influencing factors

被引：0
|
作者：
Peng, Yongde [1 ]
Zhang, Bin [2 ]
Hou, Jianing [2 ]
机构：
[1] Shanghai First Peoples Hosp, Shanghai, Peoples R China
[2] Lilly Suzhou Pharmaceut Co Ltd, Shanghai, Peoples R China
来源：
DIABETES-METABOLISM RESEARCH AND REVIEWS | 2019年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1524615
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Consistency of treatment effect across the range of baseline HbA1c in patients with Type 2 diabetes treated with once-weekly dulaglutide or comparators in AWARD-1,-5 and-6
    Gentilella, R.
    Sesti, G.
    Buzzetti, R.
    Vazquez, L. A.
    Nicolay, C.
    DIABETIC MEDICINE, 2016, 33 : 191 - 192
  • [32] A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA
    Pierre Johansen
    Barnaby Hunt
    Neeraj N. Iyer
    Tam Dang-Tan
    Richard F. Pollock
    Advances in Therapy, 2019, 36 : 1190 - 1199
  • [33] Efficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c
    Abdul-Ghani, Muhammad
    Migahid, Osama
    Megahed, Ayman
    DeFronzo, Ralph A.
    Zirie, Mahmoud
    Jayyousi, Amin
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2017, 102 (07): : 2162 - 2170
  • [34] Efficacy and Safety of Empagliflozin (EMPA) in Younger, Overweight/Obese Patients with Type 2 Diabetes (T2DM) with HbA1c ≥8%
    Merker, Ludwig
    Lund, Soren S.
    Hantel, Stefan
    Salsali, Afshin
    Kim, Gabriel
    Broedl, Uli C.
    Woerle, Hans J.
    Hach, Thomas
    DIABETES, 2014, 63 : A280 - A281
  • [35] Sustained reduction in HbA1c during one-year treatment with vildagliptin in patients with type 2 diabetes (T2DM)
    Dejager, Sylvie
    Lebeaut, Alexandre
    Couturier, Andre
    Schweizer, Anja
    DIABETES, 2006, 55 : A29 - A29
  • [36] Tolerability, Safety, PK/PD of Once-Weekly Administration of GLP-1 Analogue in T2DM Patients in China and US
    Liu, Ying
    Lv, Yuan
    Guo, Xiaohui
    Zhao, Caiyun
    Zhang, Junqing
    Wei, Minji
    Tracey, Gregory J.
    Lasseter, Kenneth C.
    Xu, Michael
    DIABETES, 2017, 66 : A296 - A296
  • [37] Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2-4 and 10
    Capehorn, Matthew
    Ghani, Yasmin
    Hindsberger, Charlotte
    Johansen, Pierre
    Jodar, Esteban
    DIABETES THERAPY, 2020, 11 (05) : 1061 - 1075
  • [38] Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA
    Pierre Johansen
    Barnaby Hunt
    Neeraj N. Iyer
    Tam Dang-Tan
    Richard F. Pollock
    Advances in Therapy, 2019, 36 : 1200 - 1200
  • [39] Impact of Once-Weekly Semaglutide on eGFR and Hemoglobin A1c (HbA1c) among Patients with Type 2 Diabetes and CKD: An Observational Study
    Amamoo, James J.
    Sheth, Sunny T.
    Brady, Brenna L.
    Tran, Anh Thu
    Xie Lin
    Noone, Josh
    Mehanna, Sherif
    Bakris, George L.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [40] HBA1C REDUCTION WITH DIGITAL HEALTH DEVICES IN TYPE 2 DIABETES (T2DM): A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
    Lee, F.
    Han-Burgess, E.
    Kennedy, A.
    Serafini, P.
    Pourrahmat, M. M.
    Breznen, B.
    VALUE IN HEALTH, 2023, 26 (06) : S297 - S297
12345